Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPRO-2018
- Development stage
- Unknown
- Lead developer
- TRIZ Biopharma Innovations
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SPRO-2018 is a veterinary antiviral drug developed by TRIZ Biopharma Innovations, utilizing a novel 'quasi-living system' based on self-organizing RNA technology. Designed using the TRIZ (Theory of Inventive Problem Solving) methodology, the therapeutic is engineered to be dynamic and self-adaptive, allowing it to adjust its structure to biological targets in response to the patient's needs. It is indicated for the treatment of a wide range of viral infections in animals, including severe cases, and has demonstrated rapid therapeutic manifestation. SPRO-2018 has received regulatory approval for production and application as a veterinary medicine.
Beyond the preview
Go deeper on SPRO-2018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPRO-2018.